Paclitaxel: cost–effectiveness in ovarian cancer

References

• Hoskins WJ, Perez CA, Young RC et al. Principles and Practice of Gynecologic Oncology. Lippincott Williams and Wilkins, PA, USA (2000).
   Google Scholar
• Abu-Rustum NR, Aghajanian C. Management of malignant germ cell tumors of the ovary. Semin. Oncol. 25(2), 235–242 (1998).
   PubMed Web of Science ®Google Scholar
• Jemal A, Murray T, Ward E et al. Cancer statistics, 2005. CA Cancer J. Clin. 55(1), 10–30 (2005).
   PubMed Web of Science ®Google Scholar
• Bray F, Loos AH, Tognazzo S, La Vecchia C. Ovarian cancer in Europe: cross-sectional trends in incidence and mortality in 28 countries, 1953–2000. Int. J. Cancer 113(6), 977–990 (2005).
   PubMed Web of Science ®Google Scholar
• McGuire WP, Hoskins WJ, Brady MF et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N. Engl. J. Med. 334(1), 1–6 (1996).
   PubMed Web of Science ®Google Scholar
• Young RC, Walton LA, Ellenberg SS et al. Adjuvant therapy in stage I and stage II epithelial ovarian cancer. Results of two prospective randomized trials. N. Engl. J. Med. 322(15), 1021–1027 (1990).
   PubMed Web of Science ®Google Scholar
• Bertone-Johnson ER. Epidemiology of ovarian cancer: a status report. Lancet 365(9454), 101–102 (2005).
   PubMed Web of Science ®Google Scholar
• Struewing JP, Hartge P, Wacholder S et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N. Engl. J. Med. 336(20), 1401–1408 (1997).
   PubMed Web of Science ®Google Scholar
• Ford D, Easton DF, Bishop DT, Narod SA, Goldgar DE. Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Lancet 343(8899), 692–695 (1994).
   PubMed Web of Science ®Google Scholar
• Chung DC, Rustgi AK. The hereditary nonpolyposis colorectal cancer syndrome: genetics and clinical implications. Ann. Intern. Med. 138(7), 560–570 (2003).
   PubMed Web of Science ®Google Scholar
• Paulsen T, Kaern J, Kjaerheim K, Trope C, Tretli S. Symptoms and referral of women with epithelial ovarian tumors. Int. J. Gynaecol. Obstet. 88(1), 31–37 (2005).
   PubMed Web of Science ®Google Scholar
• van Nagell JR Jr, DePriest PD, Reedy MB et al. The efficacy of transvaginal sonographic screening in asymptomatic women at risk for ovarian cancer. Gynecol. Oncol. 77(3), 350–356 (2000).
   PubMed Web of Science ®Google Scholar
• Meyer T, Rustin GJ. Role of tumour markers in monitoring epithelial ovarian cancer. Br. J. Cancer 82(9), 1535–1538 (2000).
   PubMed Web of Science ®Google Scholar
• Fung MF, Bryson P, Johnston M, Chambers A. Screening postmenopausal women for ovarian cancer: a systematic review. J. Obstet. Gynaecol. Can. 26(8), 717–728 (2004).
   PubMedGoogle Scholar
• Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J. Clin. Oncol. 20(5), 1248–1259 (2002).
   PubMed Web of Science ®Google Scholar
• Piccart MJ, Bertelsen K, James K et al. Randomized intergroup trial of cisplatin–paclitaxel versus cisplatin–cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J. Natl Cancer Inst. 92(9), 699–708 (2000).
   PubMed Web of Science ®Google Scholar
• Neijt JP, Engelholm SA, Tuxen MK et al. Exploratory Phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer. J. Clin. Oncol. 18(17), 3084–3092 (2000).
   PubMed Web of Science ®Google Scholar
• du Bois A, Luck HJ, Meier W et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J. Natl Cancer Inst. 95(17), 1320–1329 (2003).
   PubMed Web of Science ®Google Scholar
• Ozols RF, Bundy BN, Greer BE et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J. Clin. Oncol. 21(17), 3194–3200 (2003).
   PubMed Web of Science ®Google Scholar
• Gordon AN, Fleagle JT, Guthrie D et al. Recurrent epithelial ovarian carcinoma: a randomized Phase III study of pegylated liposomal doxorubicin versus topotecan. J. Clin. Oncol. 19(14), 3312–3322 (2001).
   PubMed Web of Science ®Google Scholar
• Thigpen JT, Aghajanian CA, Alberts DS et al. Role of pegylated liposomal doxorubicin in ovarian cancer. Gynecol. Oncol. 96(1), 10–18 (2005).
   PubMed Web of Science ®Google Scholar
• Parmar MK, Ledermann JA, Colombo N et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet 361(9375), 2099–2106 (2003).
   PubMed Web of Science ®Google Scholar
• Doyle C, Crump M, Pintilie M, Oza AM. Does palliative chemotherapy palliate? Evaluation of expectations, outcomes, and costs in women receiving chemotherapy for advanced ovarian cancer. J. Clin. Oncol. 19(5), 1266–1274 (2001).
   PubMed Web of Science ®Google Scholar
• Rowinsky EK, Donehower RC. Paclitaxel (Taxol). N. Engl. J. Med. 332(15), 1004–1014 (1995).
   PubMed Web of Science ®Google Scholar
• Berger K, Fischer T, Szucs TD. Cost-effectiveness analysis of paclitaxel and cisplatin versus cyclophosphamide and cisplatin as first-line therapy in advanced ovarian cancer. A European perspective. Eur. J. Cancer 34(12), 1894–1901 (1998).
   PubMed Web of Science ®Google Scholar
• Elit LM, Gafni A, Levine MN. Economic and policy implications of adopting paclitaxel as first-line therapy for advanced ovarian cancer: an Ontario perspective. J. Clin. Oncol. 15(2), 632–639 (1997).
   PubMed Web of Science ®Google Scholar
• Limat S, Woronoff-Lemsi MC, Menat C, Madroszyk-Flandin A, Merrouche Y. From randomised clinical trials to clinical practice: a pragmatic cost-effectiveness analysis of paclitaxel in first-line therapy for advanced ovarian cancer. Pharmacoeconomics 22(10), 633–641 (2004).
   PubMed Web of Science ®Google Scholar
• McGuire W, Neugut AI, Arikian S, Doyle J, Dezii CM. Analysis of the cost-effectiveness of paclitaxel as alternative combination therapy for advanced ovarian cancer. J. Clin. Oncol. 15(2), 640–645 (1997).
   PubMed Web of Science ®Google Scholar
• Messori A, Trippoli S, Becagli P, Tendi E. Pharmacoeconomic profile of paclitaxel as a first-line treatment for patients with advanced ovarian carcinoma. A lifetime cost-effectiveness analysis. Cancer 78(11), 2366–2373 (1996).
   PubMed Web of Science ®Google Scholar
• Neymark N, Gorlia T, Adriaenssen I, Baron B, Piccart M. Cost effectiveness of paclitaxel/cisplatin compared with cyclophosphamide/cisplatin in the treatment of advanced ovarian cancer in Belgium. Pharmacoeconomics 20(7), 485–497 (2002).
   PubMed Web of Science ®Google Scholar
• Ortega A, Dranitsaris G, Sturgeon J, Sutherland H, Oza A. Cost-utility analysis of paclitaxel in combination with cisplatin for patients with advanced ovarian cancer. Gynecol. Oncol. 66(3), 454–463 (1997).
   PubMed Web of Science ®Google Scholar
• Walker HSG, Bacon M, Eisenhaeur E, Bacon E, Tu D, Zee B. Comparative cost-effectiveness of paclitaxel–cisplatin (TP) vs. cyclophosphamide–cisplatin (CP) in women with advanced epithelial ovarian cancer: results from a randomized trial. Proc. Am. Soc. Clin. Oncol. (2000) (Abstract 1501).
   Google Scholar
• Covens A, Boucher S, Roche K et al. Is paclitaxel and cisplatin a cost-effective first-line therapy for advance ovarian carcinoma? Cancer 77(10), 2086–2091 (1996).
   PubMed Web of Science ®Google Scholar
• Tengs TO. Cost-effectiveness versus cost-utility analysis of interventions for cancer: does adjusting for health-related quality of life really matter? Value Health 7(1), 70–78 (2004).
   PubMed Web of Science ®Google Scholar
• Max W, Rice DP, Sung HY et al. The economic burden of gynecologic cancers in California, 1998. Gynecol. Oncol. 88(2), 96–103 (2003).
   PubMed Web of Science ®Google Scholar
• See HT, Kavanagh JJ. Novel agents in epithelial ovarian cancer. Cancer Invest. 22(Suppl. 2), 29–44 (2004).
   PubMed Web of Science ®Google Scholar
• Vasey PA, Jayson GC, Gordon A et al. Phase III randomized trial of docetaxel–carboplatin versus paclitaxel–carboplatin as first-line chemotherapy for ovarian carcinoma. J. Natl Cancer Inst. 96(22), 1682–1691 (2004).
   PubMed Web of Science ®Google Scholar
• Kristensen GB, Vergote I, Stuart G et al. First-line treatment of ovarian cancer FIGO stages IIb–IV with paclitaxel/epirubicin/carboplatin versus paclitaxel/carboplatin. Int. J. Gynecol. Cancer 13(Suppl. 2), 172–177 (2003).
   PubMed Web of Science ®Google Scholar
• Copeland LJ, Bookman M, Trimble E. Clinical trials of newer regimens for treating ovarian cancer: the rationale for Gynecologic Oncology Group Protocol GOG 182-ICON5. Gynecol. Oncol. 90(2 Pt 2), S1–S7 (2003).
   PubMed Web of Science ®Google Scholar
• Magazzini L, Pammolli F, Riccaboni M. Dynamic competition in pharmaceuticals. Patent expiry, generic penetration, and industry structure. Eur. J. Health Econ. 5(2), 175–182 (2004).
   PubMedGoogle Scholar
• Garber K. Improved paclitaxel formulation hints at new chemotherapy approach. J. Natl Cancer Inst. 96(2), 90–91 (2004).
   PubMedGoogle Scholar
• Kruijtzer CM, Boot H, Beijnen JH et al. Weekly oral paclitaxel as first-line treatment in patients with advanced gastric cancer. Ann. Oncol. 14(2), 197–204 (2003).
   PubMed Web of Science ®Google Scholar